Development of New Therapies for Chronic Hepatitis B [Hosted by NIAID]
AGENDA:
– Welcome | John Ward, Director, CGHE
– Introductory Remarks | Jeanne Marrazzo, Director, NIAID, NIH
– HBV replication and natural history | Jianming Hu, Professor, Department of Microbiology and Immunology, Penn State Cancer Institute
– Current treatment | Anna Lok, Assistant Dean for Clinical Research, University of Michigan
New treatments in development:
– Entry inhibitors: Stephan Urban, Head, Translational Virology, German Center for Infection Research (DZIF) – Heidelberg Partner Site, Heidelberg Germany
– Capsid assembly modulators (CAMs): Adam Zlotnick, Distinguished Professor of Molecular and Cellular Biochemistry, Indiana University
– Finding cccDNA inhibitors: Haitao Guo, Professor, Department of Microbiology and Immunology and Co-Leader, Cancer Virology Program, UPMC Hillman Cancer Center, University of Pittsburgh
– Immunomodulatory strategies | Barbara Rehermann, Chief of the Immunology, Section Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH
– Public health perspective (HBV elimination) | Chari Cohen, President, Hepatitis B Foundation
Panel + community representative discussions |
– Anna Lok
– Chari Cohen
– John Ward